Zoetis

EQS-News: Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides

Retrieved on: 
Thursday, July 6, 2023
Peptide, Protein, Partnership, Research, Health, Therapy, Dicarboxylic acid, Fine chemical, Zoetis

Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics.

Key Points: 
  • Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics.
  • Pepteins are an underdeveloped class of molecules located between PEPTides and protEINS (with a length of 30-300 amino acids).
  • To date, peptein production via chemical synthesis or recombinant approaches is cumbersome, leading to time and resource-intensive development programs.
  • The partnership collaboration with Zoetis is another milestone for Numaferm, demonstrating the value of our proprietary technologies for pharma projects and beyond.”

Zoetis to Host Webcast and Conference Call on Second Quarter 2023 Financial Results

Retrieved on: 
Friday, June 30, 2023
Biotechnology, Pharmaceutical, Health, Veterinary, Inc., Webcast, Zoetis, NYSE, Management, Broadcasting

(NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023.

Key Points: 
  • (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023.
  • Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call.
  • Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations .
  • A replay of the webcast will be made available on Aug. 8, 2023.

Zoetis Releases 2022 Sustainability Report to Share Progress in Building a Better Future for People, Animals and the Planet

Retrieved on: 
Thursday, June 15, 2023
Other Health, Health, Other Philanthropy, Philanthropy, Veterinary, Sustainability reporting, Farmer, Electricity, Livestock, TCFD, Sustainable Development Goals, Incidence, Sustainability accounting, Sustainability Accounting Standards Board, Cattle, ESG, Bill & Melinda Gates Foundation, Disease, Corporate Affairs, Research, Mycoplasma bovis, United, UN, Bill, Vaccine, Global Village Foundation, Gender equality, Poultry, Biotechnology, Aquaculture, Communication, Disclosure, Sustainable Development Goal 1, Chief sustainability officer, Carbon, Chicken, Creativity, Ruminant, DE, Animal, Methane, Task force, United Nations, Veterinary medicine, Workplace, Woman, GHG, Animal Health, Student, Community, Genetic testing, Renewable energy, Management, Zoetis

The report highlights the company’s journey to advance sustainability in Animal Health for a better future through specific actions that support Communities, Animals and the Planet.

Key Points: 
  • The report highlights the company’s journey to advance sustainability in Animal Health for a better future through specific actions that support Communities, Animals and the Planet.
  • Specifically, the Zoetis Foundation provided grants of $2.5 million in scholarships to veterinary students to support more than 500 students.
  • For more detailed disclosure on the company’s ESG programs, practices and policies, please see zoetis.com/sustainability or download Zoetis’ 2022 Sustainability Report .
  • Zoetis will continue to share updates on its sustainability activities, including progress against its Driven to Care goals, and report annually.

Dr. Maureen Dower Joins PetVivo Holdings, Inc. as a Senior Technical Services Veterinarian

Retrieved on: 
Thursday, June 1, 2023
Pennsylvania State University, Osteoarthritis, Purdue University School of Aeronautics and Astronautics, Therapy, Horse, Veterinarian, Zoetis, Quality of life, Maureen, Athlete, Doctorate, Animal, Dog, Veterinary medicine, Purdue University, Medical device

"We are thrilled to have Maureen join the PetVivo team.” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Dr.

Key Points: 
  • "We are thrilled to have Maureen join the PetVivo team.” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Dr.
  • Dower brings a wealth of experience to our team as an expert in biovigilance systems, veterinary products customer service, as well as the therapeutic treatment of animals."
  • Dr. Dower has served in various capacities, contributing to product development, regulatory guidance, technical sales training and customer service with companies such as Pfizer Animal Health and Zoetis Animal Health.
  • Dr. Dower’s involvement with some of the leading brands for veterinary products brings a wealth of experience to PetVivo.

Zoetis to Participate in the Stifel 2023 Jaws and Paws Conference

Retrieved on: 
Tuesday, May 30, 2023
Health, Veterinary, Pets, Consumer, Inc., Zoetis, Conference, NYSE, Online shopping

Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2023 Jaws and Paws Conference on Wednesday, May 31, 2023.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2023 Jaws and Paws Conference on Wednesday, May 31, 2023.
  • Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts.
  • Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations .
  • A replay of the presentation will also be available on the Zoetis website at the conclusion of the event.

Zoetis Holds Investor Day and Presents Strategy to Shape Animal Health for the Next Decade

Retrieved on: 
Thursday, May 25, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, The Next Decade (book), Inc., Research and development, Livestock, Animal Health, Kidney, Development, Dermatology, Animal, Investment, Growth, Capital, Cardiology, NYSE, Management, Renewable energy, Zoetis

Delivering growth in a dynamic and resilient industry by innovating and growing faster than the market.

Key Points: 
  • Delivering growth in a dynamic and resilient industry by innovating and growing faster than the market.
  • Zoetis sees long-term sustainable growth driven by new products and lifecycle innovations for companion animals and livestock.
  • “We pride ourselves on shaping animal health and creating new markets based on game-changing innovations.
  • A live webcast of the investor day presentations, along with supporting materials, can be accessed by the general public today starting at 9:00 a.m.

Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs

Retrieved on: 
Friday, May 5, 2023
Medical Supplies, Biotechnology, FDA, Other Health, Health, Pharmaceutical, Pets, Medical Devices, Consumer, Veterinary, Clinical Trials, Exercise, Osteoarthritis, Inc., Blood urea nitrogen, Prevalence, Senior, Veterinarian, Overalls, European Medicines Agency, State university system, Human, Quality of life, Zoetis, Dermatitis, North Carolina State University, EMA, Urinary tract infection, Translational research, Dog, Pain management, Nerve growth factor, NGF, Chronic pain, Regulation of tobacco by the U.S. Food and Drug Administration, BUN, NYSE, Food, Vaccine, Hunting, OA, Pain

Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.
  • Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life.
  • The pain of OA can impact a dog’s physical and emotional health.
  • This once monthly injection works differently from other pain medications – it’s unique mode of action targets Nerve Growth Factor (NGF), a key component of OA pain.

Zoetis Announces First Quarter 2023 Results

Retrieved on: 
Thursday, May 4, 2023
Veterinary, COVID-19, Medical Devices, Medical Supplies, Hospitals, FDA, Other Health, Biotechnology, General Health, Health, Vaccine, International, Demodicosis, Poultry, Livestock, Mycoplasma bovis, Sheep, Dermatology, Acquisition, Animal, Inc., Dog, Cattle, European, Growth, Webcast, NYSE, Disease, Cat, Video game, Veterinary medicine, EU, Zoetis, Lawsonia

(NYSE: ZTS) today reported its financial results for the first quarter of 2023 and maintained its guidance for full year 2023.

Key Points: 
  • (NYSE: ZTS) today reported its financial results for the first quarter of 2023 and maintained its guidance for full year 2023.
  • The company reported revenue of $2.0 billion for the first quarter of 2023, an increase of 1% compared with the first quarter of 2022.
  • On an operational1 basis, revenue for the first quarter of 2023 increased 4% compared with the first quarter of 2022, excluding the impact of foreign currency.
  • Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review first quarter 2023 results, discuss financial guidance and respond to questions from financial analysts.

Zoetis Announces Date for 2023 Investor Day

Retrieved on: 
Monday, May 1, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, Webcast, Research and development, Inc., Zoetis, Q&A, NYSE, Research

Zoetis Inc. (NYSE:ZTS) will host an Investor Day on Thursday, May 25, 2023, at the New York Stock Exchange featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Chief Financial Officer; Robert Polzer, Ph.D., President of Research and Development; and other members of the Zoetis executive team.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) will host an Investor Day on Thursday, May 25, 2023, at the New York Stock Exchange featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Chief Financial Officer; Robert Polzer, Ph.D., President of Research and Development; and other members of the Zoetis executive team.
  • Zoetis will provide an update on the company’s strategy to deliver long-term profitable growth and value for shareholders, followed by a Q&A session.
  • A live webcast of the investor day presentations, along with supporting materials, will be available to the general public on the day of the event on the Zoetis Investor Relations website .
  • Institutional investors and analysts interested in attending should contact one of the company’s Investor Relations contacts listed on this press release.

NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Retrieved on: 
Wednesday, April 19, 2023
NRG, Medicine, University, MOA, Therapy, Evotec, Doctor of Philosophy, CSO, MND, Zoetis, Cell, ALS, Mitochondrion, Mitochondrial permeability transition pore, WEHI, SBC, MPTP, Brunel University London, R, Veterinary medicine, IND, Pharmaceutical industry, Chemistry, Biology, Pfizer

Dr Lazari brings two decades of experience in R&D gained at Charles River, Pfizer, and BioFocus DPI.

Key Points: 
  • Dr Lazari brings two decades of experience in R&D gained at Charles River, Pfizer, and BioFocus DPI.
  • NRG Therapeutics’ co-founder and CEO Neil Miller Ph.D. said, “I am delighted to welcome Vad to our team.
  • There is a substantial body of evidence demonstrating mitochondrial failure or dysfunction is common across many neurodegenerative disorders.
  • Vad Lazari Ph.D., VP of Biology at NRG Therapeutics said, “NRG’s ground-breaking discoveries pointing to the role of the mPTP in neurodegenerative diseases has enabled the discovery of small molecule mitochondrial therapeutics targeting the pore.